Expression of maspin tumor suppressor and mTOR in laryngeal carcinoma
Author links open overlay panelGinoMarioniaGiancarloOttavianoaAndreaLovatobLeonardoFranzaLuigiaBandolinaGiacomoControaLucianoGiacomellicLaraAlessandrinicRobertoStramaredCosimode FilippiscStellaBlandamurac
a
Department of Neuroscience DNS, Otolaryngology Section, University of Padova, Padova, Italy
b
Department of Neuroscience DNS, Audiology Unit, University of Padova, Treviso, Italy
c
Department of Medicine DIMED, University of Padova, Padova, Italy
d
Radiology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Received 19 October 2019, Available online 23 October 2019.
Abstract
Purpose
The main aim of this study was to conduct a preliminary investigation into the possible relationship between mTOR and the nuclear tumor suppressor maspin in laryngeal carcinoma (LSCC).
Materials and methods
mTOR expression and maspin pattern were ascertained, also with the aid of image analysis in 79 consecutive LSCCs.
Results
Considering the whole series, univariate statistical analysis identified significant differences in the distributions by lymph node status (N0 vs N+) between two subgroups of patients with and without loco-regional carcinoma recurrences (p = 0.017). The log-rank test also showed a shorter disease-free survival (DFS) in pN+ patients (p = 0.0008). mTOR expression was significantly higher in patients whose disease recurred (p = 0.009). The DFS rate was also significantly shorter in cases of LSCC with an mTOR expression ≥11.55% (p = 0.049). Multivariate analysis showed that N status (p = 0.002) and mTOR expression (p = 0.037) retained their prognostic significance in relation to cancer recurrence.
In a subgroup of LSCCs with a non-nuclear maspin pattern, mTOR expression was significantly higher in patients whose disease recurred. Multivariate analysis disclosed that N stage (p = 0.012) retained its independent prognostic significance for disease recurrence in this setting. mTOR expression showed a trend towards independent significance in terms of carcinoma recurrence (p = 0.083).
Conclusions
mTOR inhibitors seem promising for use in cancer therapies. Further investigations are needed on the prospects of incorporating modern mTOR inhibitors in multimodality or multitarget strategies against advanced LSCCs, also considering the role and expression of tumor suppressor genes.
Keywords
Laryngeal squamous cell carcinomamTORNuclear maspinTumor suppressorsPrognosis
View full text
© 2019 Published by Elsevier Inc.
Author links open overlay panelGinoMarioniaGiancarloOttavianoaAndreaLovatobLeonardoFranzaLuigiaBandolinaGiacomoControaLucianoGiacomellicLaraAlessandrinicRobertoStramaredCosimode FilippiscStellaBlandamurac
a
Department of Neuroscience DNS, Otolaryngology Section, University of Padova, Padova, Italy
b
Department of Neuroscience DNS, Audiology Unit, University of Padova, Treviso, Italy
c
Department of Medicine DIMED, University of Padova, Padova, Italy
d
Radiology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Received 19 October 2019, Available online 23 October 2019.
Figures (2)
Abstract
Purpose
The main aim of this study was to conduct a preliminary investigation into the possible relationship between mTOR and the nuclear tumor suppressor maspin in laryngeal carcinoma (LSCC).
Materials and methods
mTOR expression and maspin pattern were ascertained, also with the aid of image analysis in 79 consecutive LSCCs.
Results
Considering the whole series, univariate statistical analysis identified significant differences in the distributions by lymph node status (N0 vs N+) between two subgroups of patients with and without loco-regional carcinoma recurrences (p = 0.017). The log-rank test also showed a shorter disease-free survival (DFS) in pN+ patients (p = 0.0008). mTOR expression was significantly higher in patients whose disease recurred (p = 0.009). The DFS rate was also significantly shorter in cases of LSCC with an mTOR expression ≥11.55% (p = 0.049). Multivariate analysis showed that N status (p = 0.002) and mTOR expression (p = 0.037) retained their prognostic significance in relation to cancer recurrence.
In a subgroup of LSCCs with a non-nuclear maspin pattern, mTOR expression was significantly higher in patients whose disease recurred. Multivariate analysis disclosed that N stage (p = 0.012) retained its independent prognostic significance for disease recurrence in this setting. mTOR expression showed a trend towards independent significance in terms of carcinoma recurrence (p = 0.083).
Conclusions
mTOR inhibitors seem promising for use in cancer therapies. Further investigations are needed on the prospects of incorporating modern mTOR inhibitors in multimodality or multitarget strategies against advanced LSCCs, also considering the role and expression of tumor suppressor genes.
Keywords
Laryngeal squamous cell carcinomamTORNuclear maspinTumor suppressorsPrognosis
View full text
© 2019 Published by Elsevier Inc.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου